A Practical Approach to MRD: Testing with clonoSEQ image

A Practical Approach to MRD: Testing with clonoSEQ

Oct 27, 2021
07:00PM - 08:15PM EDT
Online Event
Overview

MRD (Minimal Residual Disease) is one of the strongest predictors of outcomes in blood cancers, including myeloma. While new treatments today are helping myeloma patients achieve complete responses, a small number of cancer cells can remain in your body and may cause your myeloma to return. Using highly sensitive tests like the clonoSEQ MRD tests to test results what cancer cells, if any, remain in your body after achieving a complete response is needed in order to asses therapy responses over time and be aware of what your myeloma status truly is.
Learn more with us from the Adaptive Biotechnology team and come with your questions!

Agenda
07:00 PM
Introduction
Audrey Burton-Bethke
Audrey introduces the agenda of the event and featured speakers Robin Dullea and Mark Schliekelman.
07:05 PM
Presentation
Robin Dullea and Mark Schliekelman
Robin Dullea and Mark Schliekelman tell us about highly sensitive tests like the clonoSEQ MRD, to test what cancer cells remain in your body in order to assess therapy responses over time and be aware of what your myeloma status truly is.  
07:25 PM
Intro Q&A Discussion
Dennis Verducci, Robin Dullea, and Mark Schliekelman
We begin the Q&A session by introducing Dennis and discussing common Q&As about the clonoSEQ test and MRD clinical use. 
07:45 PM
Questions and Answers
Audience
Type your questions in the Q&A feature for any of our panelists and we will answer them! 
Speakers & Moderators
Healthtree contact Robin Dullea

Robin Dullea

Robin Dullea is the Associate Director of clonoSEQ Marketing at Adaptive Biotechnologies. Throughout her 20+ year career in medical marketing Robin has been passionate about empowering patients with education and information to help improve their lives. She lives in Seattle with her husband and 2 energetic dogs.
Healthtree contact Mark Schliekelman

Mark Schliekelman

Experienced Medical Science Liaison with with deep understanding of Oncology and Pharmaceuticals . Skilled in Scientific Review, Molecular Biology, Biotechnology, Cell Culture, and Scientific Writing. Strong research professional with a Doctor of Philosophy (Ph.D.) focused in Genetics and Molecular Biology from UNC Chapel Hill. I see my role: As identifying engaging and maintaining relationships with Key Opinion Leaders. To be a collaborative and supportive partner with business and research professionals. As a Medical Affairs Facilitator and subject matter expert with a demonstrated ability effectively communicate. To provide information that is clear, concise and clinically relevant. To ask provocative questions that challenge current assumptions. Provide thoughtful answers to queries and concerns. Give peer level support in ensuring well-run research and trials. I consider myself to be a person of integrity; principled, diplomatic, calm, thoughtful and reflective. I have a deep understanding of oncology and am able to go toe to toe with Key Opinion Leaders in an engaging scientific exchange.
Healthtree contact Dennis Verducci MSN, RN, NP-BC, OCN

Dennis Verducci MSN, RN, NP-BC, OCN

Dennis has vast experience with multiple myeloma after treating patients in various capacities, such as on the bone marrow transplant unit and outpatient teams of prestigious centers such as Hackensack, John Theurer, and Memorial Sloan-Kettering Cancer Center (MSK). He now is working as a Nurse Practitioner at the University of Miami alongside renowned myeloma specialist, Dr. Ola Landgren.